Myriad Genetics, Inc. (MYGN) Stock

Myriad Genetics, Inc. (MYGN) is a Healthcare stock trading at $3.24 (as of 2026-09-02), with a market capitalization of $309.90M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Myriad Genetics, Inc. develops and commercializes genetic tests used in clinical decision-making, including molecular diagnostic assays for oncology and women’s and mental health. Its offerings include germline and tumor companion diagnostics and prognostic tests such as MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict, which it sells in the United States and internationally.

Understand Myriad Genetics, Inc.: how it makes money

Myriad Genetics sells molecular diagnostic tests for hereditary cancer, prenatal screening, and mental health pharmacogenomics, earning revenue through per-test fees paid by clinicians and patients. Cancer testing drives 60% of revenue, with prenatal and mental health each adding roughly 20%, making growth dependent on ongoing clinical adoption.

Each assay is a separate, high-margin revenue event, but the fixed lab and sales-force infrastructure means volumes must stay elevated to absorb the operating overhead and turn a profit.

Revenue by segment (latest quarter)
Cancer Care	$0.1B
Prenatal Health	$0.0B
Mental Health	$0.0B

Business quality (Weak): A 67% gross margin confirms attractive per-test economics, yet a negative 20% operating margin and -46% ROE show the cost base is too heavy for current volumes. The business earns a 'Weak' grade until revenue stabilizes or costs are restructured.

Bull case

Per-test pricing still climbing: Average revenue per test rose 2% in the period, indicating the mix is shifting toward higher-value multi-gene panels rather than commoditizing. That subtle pricing lift is a leading sign the core assays retain clinical differentiation.
Product economics stay resilient: Gross margin held at 67% even as total revenue fell 11% year over year, showing the underlying tests keep their per-unit contribution. If volumes stabilize, that margin base converts quickly into operating leverage.

Bear case

Cancer line still shrinking: Cancer Care Continuum generated $120M (60% of revenue) in the quarter, and the company-wide 11% YoY revenue decline shows this dominant product line is the source of the softness, not a rounding-error segment. Slowing the core engine is the hardest kind of deceleration to reverse.
Fixed costs outpace a smaller top line: Operating margin sits at -20% and ROE at -46%, meaning the lab network, sales force, and R&D spend cannot be trimmed quickly enough to match declining test volumes. Until revenue stabilizes, the balance sheet will continue to absorb operating losses.

Valuation — source: SEC EDGAR (first-party)
Price	$3.24
Market Cap	$309.90M
Price / Book	1.02
Price / Sales	0.38

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$824.50M
Net Margin	-44.4%
Revenue Growth (YoY)	-10.5%
EPS Growth (YoY)	-87.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	-2.00 (distress)
Piotroski F-Score	5/9 (moderate)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	ORBIMED ADVISORS LLC ($122.88M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Samraat S. Raha
Employees	2,700
Country	US
IPO Date	1995-10-06

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

Data as of 2026-09-02.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.